Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis

April W. Armstrong, Steven R. Feldman, Neil J. Korman, Xiangyi Meng, Adriana Guana, Judit Nyirady, Vivian Herrera, Yang Zhao

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Background: Conventional measurements for assessing psoriasis treatment effects capture improvements at fixed, pre-specified timepoints, failing to account for cumulative clinical benefit over time. Objective: Explore the innovative concept of “cumulative clinical benefit” by examining the effect of secukinumab over 52 weeks in moderate-to-severe psoriasis patients. Methods: Cumulative clinical benefit was determined as the area-under-the-curve of the percentage of responders over 52 weeks (AUC0–52 wks), using pooled data from two phase III trials for patients receiving secukinumab (300 or 150 mg) or etanercept. Results: Normalized cumulative benefit with secukinumab 300 mg, secukinumab 150 mg, and etanercept was 74.2%, 63.2%, and 50.5%, respectively, for PASI 75; 58.0%, 42.5%, and 29.5%, respectively, for PASI 90; 32.3%, 18.8%, and 8.7%, respectively, for PASI 100; and 58.3%, 47.9%, and 38.3%, respectively, for DLQI 0/1. 52-week PASI 75 clinical benefit ratios for secukinumab 300 and 150 mg versus etanercept were 1.47 and 1.25, respectively; the ratio of the two secukinumab doses was 1.17, favoring 300 mg. Limitations: Post hoc analysis. Conclusion: Cumulative clinical benefit estimated by AUC0-52 wks is a novel measure for comparing psoriasis treatments. Secukinumab 300 mg provides greater cumulative clinical benefit than secukinumab 150 mg; both provide greater cumulative benefit than etanercept.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalJournal of Dermatological Treatment
DOIs
StateAccepted/In press - Aug 19 2016
Externally publishedYes

Keywords

  • Biologics
  • cumulative clinical benefit
  • etanercept
  • interleukin-17A
  • psoriasis
  • secukinumab

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis'. Together they form a unique fingerprint.

  • Cite this